MA55761A - Formulations et anticorps anti-cd38 - Google Patents

Formulations et anticorps anti-cd38

Info

Publication number
MA55761A
MA55761A MA055761A MA55761A MA55761A MA 55761 A MA55761 A MA 55761A MA 055761 A MA055761 A MA 055761A MA 55761 A MA55761 A MA 55761A MA 55761 A MA55761 A MA 55761A
Authority
MA
Morocco
Prior art keywords
antibodies
formulations
Prior art date
Application number
MA055761A
Other languages
English (en)
French (fr)
Inventor
Béatrice Cameron
Blondel Marielle Chiron
Jacques Dumas
Alain Fournier
Jonathan Kingsbury
Cendrine Lemoine
Brian Murray
Nathan Ostberg
Sanket Patke
Angela Virone-Oddos
Zichuan Zhang
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA55761A publication Critical patent/MA55761A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MA055761A 2019-04-23 2020-04-23 Formulations et anticorps anti-cd38 MA55761A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962837518P 2019-04-23 2019-04-23
US201962859699P 2019-06-10 2019-06-10
EP20305146 2020-02-17
EP20305145 2020-02-17

Publications (1)

Publication Number Publication Date
MA55761A true MA55761A (fr) 2022-03-02

Family

ID=70739160

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055761A MA55761A (fr) 2019-04-23 2020-04-23 Formulations et anticorps anti-cd38

Country Status (15)

Country Link
EP (1) EP3958898A1 (he)
JP (1) JP7602485B2 (he)
KR (1) KR20220003562A (he)
CN (2) CN114269375A (he)
AU (1) AU2020261039A1 (he)
BR (1) BR112021021060A2 (he)
CA (1) CA3137365A1 (he)
CO (1) CO2021015462A2 (he)
IL (1) IL287477A (he)
MA (1) MA55761A (he)
MX (1) MX2021012967A (he)
MY (1) MY206426A (he)
SG (1) SG11202111602YA (he)
TW (1) TWI878289B (he)
WO (1) WO2020219681A1 (he)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023109928A1 (zh) * 2021-12-16 2023-06-22 上海宝济药业有限公司 抗免疫球蛋白降解酶酶切的Fc变体
WO2024023843A1 (en) * 2022-07-26 2024-02-01 Dr. Reddy’S Laboratories Limited A pharmaceutical formulation of a therapeuticantibody and preparations thereof
WO2025245526A1 (en) * 2024-05-24 2025-11-27 Research Institute At Nationwide Children's Hospital Cd-38 protein binding compositions and methods related thereto
CN120535629B (zh) * 2025-04-22 2026-01-23 西安市中心血站（陕西省血液中心） 一种用于抑制cd38单抗对输血相容性检测干扰的抗体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005016683D1 (de) 2004-07-10 2009-10-29 Fox Chase Cancer Ct Genetisch modifizierte, menschliche, natürliche killerzellenlinien:
CN103172731A (zh) * 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
SG10201603411WA (en) * 2011-10-28 2016-07-28 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
US10617757B2 (en) * 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
DK3827845T3 (da) * 2015-11-03 2022-05-23 Janssen Biotech Inc Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
GEP20217249B (en) * 2016-06-30 2021-04-26 Inc Celltrion Stable liquid pharmaceutical preparation
SG11201910134SA (en) * 2017-05-02 2019-11-28 Merck Sharp & Dohme Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
WO2019064263A1 (en) * 2017-09-29 2019-04-04 Janssen Biotech, Inc. NOVEL FORMULATIONS FOR STABILIZING LOW DOSE ANTIBODY COMPOSITIONS
CN108752475B (zh) * 2018-06-14 2021-07-30 北京智仁美博生物科技有限公司 抗人cd38抗体及其用途

Also Published As

Publication number Publication date
JP7602485B2 (ja) 2024-12-18
CN120757645A (zh) 2025-10-10
BR112021021060A2 (pt) 2021-12-14
IL287477A (he) 2021-12-01
WO2020219681A1 (en) 2020-10-29
MX2021012967A (es) 2022-01-18
KR20220003562A (ko) 2022-01-10
EP3958898A1 (en) 2022-03-02
CO2021015462A2 (es) 2021-12-10
JP2022529502A (ja) 2022-06-22
CN114269375A (zh) 2022-04-01
CA3137365A1 (en) 2020-10-29
MY206426A (en) 2024-12-17
SG11202111602YA (en) 2021-11-29
AU2020261039A1 (en) 2021-12-09
TW202104269A (zh) 2021-02-01
TWI878289B (zh) 2025-04-01

Similar Documents

Publication Publication Date Title
EP3618871A4 (en) FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
MA52884A (fr) Anticorps anti-il-11
EP3740508A4 (en) ANTIBODIES AND VARIANTS THEREOF AGAINST TIGIT
MA53434A (fr) Anticorps anti-tigit
MA52366A (fr) Anticorps anti-tl1a optimisés
MA55600A (fr) Anticorps anti-ige
MA50359A (fr) Anticorps anti-cd38 et procédés d'utilisation
EP3999545A4 (en) ANTI-CD73 ANTIBODIES AND USE THEREOF
EP3658589C0 (en) Anti-sirp-alpha antibodies and related methods
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA49043A (fr) Formulation stable d'anticorps
MA44659A (fr) Anticorps anti-tim-3 et compositions
EP3883970A4 (en) ANTI-B7-H3 ANTIBODIES
MA48462A (fr) Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation
IL290141A (he) פורמולציות של נוגדנים אנטי-pvrig ושימושים בהם
MA55818A (fr) Anticorps et immunoconjugués de fr-alpha biparatopique
EP3883967A4 (en) CD38 AND ICAM1 ANTIBODIES AND USES THEREOF
MA71409A (fr) Constructions d'anticorps pour dll3 et cd3
EP3370770A4 (en) Subcutaneous formulations of anti-CD38 antibodies and their uses
EP3307274A4 (en) CD123 ANTIBODIES AND CONJUGATES THEREOF
IL288153A (he) פורמולציות מיוצבות המכילות נוגדנים anti-angptl3
MA47468A (fr) Anticorps anti-ilt3 et conjugués anticorps-médicament
EP3638697A4 (en) ANTI-IL1RAP ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES
MA51903A (fr) Formulations d'anticorps b7-h4
EP3941946A4 (en) CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES